AR-701 / Aridis - LARVOL DELTA

Rho-GTPase Activating Protein myosin MYO9A identified as a novel candidate gene for monogenic focal segmental glomerulosclerosis. (PubMed, Kidney Int) - "Here, we describe a rare MYO9A loss of function nonsense heterozygous mutation (p.Arg701*) as a possible contributor to disease in a sibling pair with familial FSGS/proteinuria...Thus, Myo9AR701X/+ knock-in mice recapitulate the proband FSGS phenotype, demonstrate that p.R701X Myo9A is a FSGS-causing mutation in mice and suggest that heterozygous loss-of-function MYO9A mutations may cause a novel form of human autosomal dominant FSGS. Hence, identification of MYO9A pathogenic variants in additional individuals with familial or sporadic FSGS is needed to ascertain the gene contribution to disease."

Journal • Focal Segmental Glomerulosclerosis • Glomerulonephritis • Renal Disease

Aridis Pharmaceuticals to Host Fireside Chat with Analysts to Discuss 2021 Outlook for its Lead Programs and Novel mAb Discovery Platform on December 4th, 2020 (PRNewswire) - "Aridis Pharmaceuticals, Inc....is pleased to announce a 75 minute 'Fireside Chat Forum,' with its five covering analysts will be held on December 4th, 2020 at 11:00AM EST....AR-301: Currently enrolling a Phase 3 global clinical trial in patients with ventilator associated pneumonia (VAP)...for COVID-19. Interim data expected in 1H 2021; full data in YE 2021; COVID-19 (AR-711 & 701): Developing inhaled, self-administered, at-home treatment for mild-to-moderate condition (AR-711). A clinical Phase 1/2 study to be launched in 1H 2021. Continuing characterization of monoclonal antibody cocktail (AR-701) for intravenous inpatient treatment for moderate-severe indications."

Enrollment status • New P1/2 trial • P3 data • P3 data: top line • Infectious Disease • Novel Coronavirus Disease